Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin - Hayashi, T; Fukui, T; Nakanishi, N; Yamamoto, S; Tomoyasu, M; Osamura, A; Ohara, M; Yamamoto, T; Ito, Y; Hirano, T (Cardiovasc Diabetol, 2017)